CDTX
Price
$60.72
Change
-$1.28 (-2.06%)
Updated
Aug 11, 12:43 PM (EDT)
Capitalization
1.37B
NBY
Price
$0.60
Change
+$0.01 (+1.69%)
Updated
Aug 11, 04:54 PM (EDT)
Capitalization
3.45M
Interact to see
Advertisement

CDTX vs NBY

Header iconCDTX vs NBY Comparison
Open Charts CDTX vs NBYBanner chart's image
Cidara Therapeutics
Price$60.72
Change-$1.28 (-2.06%)
Volume$200
Capitalization1.37B
NovaBay Pharmaceuticals
Price$0.60
Change+$0.01 (+1.69%)
Volume$324
Capitalization3.45M
CDTX vs NBY Comparison Chart in %
Loading...
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDTX vs. NBY commentary
Aug 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDTX is a Hold and NBY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 11, 2025
Stock price -- (CDTX: $62.00 vs. NBY: $0.59)
Brand notoriety: CDTX and NBY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDTX: 48% vs. NBY: 81%
Market capitalization -- CDTX: $1.37B vs. NBY: $3.45M
CDTX [@Biotechnology] is valued at $1.37B. NBY’s [@Biotechnology] market capitalization is $3.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDTX’s FA Score shows that 0 FA rating(s) are green whileNBY’s FA Score has 2 green FA rating(s).

  • CDTX’s FA Score: 0 green, 5 red.
  • NBY’s FA Score: 2 green, 3 red.
According to our system of comparison, NBY is a better buy in the long-term than CDTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDTX’s TA Score shows that 3 TA indicator(s) are bullish while NBY’s TA Score has 4 bullish TA indicator(s).

  • CDTX’s TA Score: 3 bullish, 5 bearish.
  • NBY’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both CDTX and NBY are a bad buy in the short-term.

Price Growth

CDTX (@Biotechnology) experienced а -1.43% price change this week, while NBY (@Biotechnology) price change was -0.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.35%. For the same industry, the average monthly price growth was +31.87%, and the average quarterly price growth was +19.42%.

Industries' Descriptions

@Biotechnology (+22.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDTX($1.37B) has a higher market cap than NBY($3.45M). CDTX YTD gains are higher at: 130.655 vs. NBY (-1.414). NBY has higher annual earnings (EBITDA): -6.8M vs. CDTX (-192.6M). CDTX has more cash in the bank: 168M vs. NBY (8.47M). NBY has less debt than CDTX: NBY (1.13M) vs CDTX (2.67M). NBY has higher revenues than CDTX: NBY (9.78M) vs CDTX (302K).
CDTXNBYCDTX / NBY
Capitalization1.37B3.45M39,785%
EBITDA-192.6M-6.8M2,831%
Gain YTD130.655-1.414-9,238%
P/E RatioN/A0.02-
Revenue302K9.78M3%
Total Cash168M8.47M1,984%
Total Debt2.67M1.13M238%
FUNDAMENTALS RATINGS
CDTX vs NBY: Fundamental Ratings
CDTX
NBY
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10013
PRICE GROWTH RATING
1..100
3453
P/E GROWTH RATING
1..100
10051
SEASONALITY SCORE
1..100
5039

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBY's Valuation (12) in the Biotechnology industry is significantly better than the same rating for CDTX (86). This means that NBY’s stock grew significantly faster than CDTX’s over the last 12 months.

NBY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CDTX (100). This means that NBY’s stock grew similarly to CDTX’s over the last 12 months.

NBY's SMR Rating (13) in the Biotechnology industry is significantly better than the same rating for CDTX (100). This means that NBY’s stock grew significantly faster than CDTX’s over the last 12 months.

CDTX's Price Growth Rating (34) in the Biotechnology industry is in the same range as NBY (53). This means that CDTX’s stock grew similarly to NBY’s over the last 12 months.

NBY's P/E Growth Rating (51) in the Biotechnology industry is somewhat better than the same rating for CDTX (100). This means that NBY’s stock grew somewhat faster than CDTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDTXNBY
RSI
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
79%
Momentum
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 20 days ago
84%
Bullish Trend 25 days ago
82%
Declines
ODDS (%)
Bearish Trend 13 days ago
90%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
82%
Aroon
ODDS (%)
Bullish Trend 4 days ago
89%
Bullish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSIGX63.900.46
+0.73%
Invesco Main Street A
LGCSX19.470.08
+0.41%
Lord Abbett Global Equity R4
CIMDX15.870.06
+0.38%
Clarkston Founders Institutional
FMCEX36.69-0.03
-0.08%
Fidelity Advisor Stock Selec Mid Cp C
RGSCX23.64-0.23
-0.96%
Virtus KAR Global Small-Cap C

CDTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDTX has been closely correlated with WINT. These tickers have moved in lockstep 94% of the time. This A.I.-generated data suggests there is a high statistical probability that if CDTX jumps, then WINT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDTX
1D Price
Change %
CDTX100%
+0.44%
WINT - CDTX
94%
Closely correlated
-6.78%
NBY - CDTX
93%
Closely correlated
+1.84%
NCNA - CDTX
93%
Closely correlated
-1.83%
TAOX - CDTX
93%
Closely correlated
+3.53%
BPTSY - CDTX
92%
Closely correlated
N/A
More

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been closely correlated with CDTX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NBY jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
+1.84%
CDTX - NBY
93%
Closely correlated
+0.44%
NCNA - NBY
93%
Closely correlated
-1.83%
WINT - NBY
92%
Closely correlated
-6.78%
TAOX - NBY
91%
Closely correlated
+3.53%
RNAC - NBY
91%
Closely correlated
-0.09%
More